Current ADC treatment trials in both adjuvant (KATHERINE trial) and metastatic settings (DESTINY03 trial) show promise for alternative HER2-positive breast cancer treatment beyond trastuzumab and standard chemotherapy [30, 31]. Here, ERBB2 is linked to breast carcinoma.